Neuronetics reports preliminary Q4 revenue $22.1M, FY2024 $74.5M; issues 2025 guidance with 12-19% growth

Neuronetics, Inc.

2024-FY EPS reported -$1.38 revenue$74,890,000

Preliminary Q4 2024 revenue $22.1M; full-year 2024 revenue $74.5M (combined with Greenbrook from Dec 9).
Closed acquisition of Greenbrook TMS Dec 9, 2024; expects over $22M annualized cost synergies.
FY2025 revenue guidance $145M-$155M, pro forma growth 12-19%; gross margin ~55%.
Expects cash flow breakeven in Q3 2025; reduced cash burn in H1 2025.
Launched Better Me Provider program with over 350 sites; FDA clearance for adolescent MDD expanded TAM by 35%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.